The Evidence Dilemma In Genomic Medicine
The Evidence Dilemma In Genomic Medicine
复制标题
DOI：
10.1377/hlthaff.27.6.1600
复制
发表时间：
2008-11-01
期刊：
影响因子：
9.7
通讯作者：
Bradley, Linda A.
中科院分区：
文献类型：
--
作者：
Khoury, Muin J.;Berg, Al;Bradley, Linda A.
基因组医学的一个持续困境是平衡科学创新的需要与将技术付诸实践的适当证据阈值。目前的低门槛允许未经证实的技术进入实践，有可能使卫生系统不堪重负。或者，设定过高的证据门槛可能会减缓将基因组学纳入实践的速度，并阻碍对研究和开发的投资。此外，不同的覆盖和报销政策可能导致获得技术的机会不同，从而加剧健康差距。迫切需要一个协作进程，以便将基因组发现从研究适当地过渡到实践。[Health Affairs 27，no. 6（2008）：1600 1611; 10.1377/hlthaff.27.6.1600]
An ongoing dilemma in genomic medicine is balancing the need for scientific innovation with appropriate evidence thresholds for moving technology into practice. The current low threshold allows unsubstantiated technologies to enter into practice, with the potential to overwhelm the health system. Alternatively, establishing an excessively high threshold for evidence could slow the integration of genomics into practice and present disincentives for investing in research and development. Also, variable coverage and reimbursement policies can lead to differential access to technology, exacerbating health disparities. There is an urgent need for a collaborative process for appropriate transition of genomic discoveries from research to practice. [Health Affairs 27, no. 6 (2008): 1600 1611; 10.1377/hlthaff.27.6.1600]